It is clear from Greta's case study that the conversion from Durogesic DTrans to subcutaneous morphine involves a number of steps and a number of calculations. Although these calculations are themselves very simple, confusion and uncertainty over how to proceed is understandable, particularly when the patch is to be removed completely and analgesia is to be continued by the subcutaneous route.
The following points are by way of general guidance but you are strongly advised if the patient is on a high dose of Durogesic DTrans to discuss such a change with your local Specialist Palliative Care Team before commencing such a course of action.
Reasons for converting a patient's medication to a subcutaneous route may include: